CTLA-4 Antigen

"CTLA-4 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.

Descriptor ID	D060908
MeSH Number(s)	D12.776.543.750.705.222.750 D23.050.301.264.894.158 D23.101.100.894.158
Concept/Terms	CTLA-4 Antigen CTLA-4 Antigen Antigen, CTLA-4 CTLA 4 Antigen Antigens, CD152 CD152 Antigens Cytotoxic T-Lymphocyte-Associated Antigen 4 Cytotoxic T Lymphocyte Associated Antigen 4 Cytotoxic T-Lymphocyte Antigen 4 Cytotoxic T Lymphocyte Antigen 4 CD152 Antigen Antigen, CD152

Below are MeSH descriptors whose meaning is more general than "CTLA-4 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
CTLA-4 Antigen [D12.776.543.750.705.222.750]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
CTLA-4 Antigen [D23.050.301.264.894.158]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
CTLA-4 Antigen [D23.101.100.894.158]

Below are MeSH descriptors whose meaning is more specific than "CTLA-4 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CTLA-4 Antigen" by people in this website by year, and whether "CTLA-4 Antigen" was a major or minor topic of these publications.

Bar chart showing 29 publications over 18 distinct years, with a maximum of 4 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
1996	0	1	1
2001	0	1	1
2002	0	1	1
2003	0	2	2
2004	0	4	4
2007	0	2	2
2008	0	1	1
2009	0	2	2
2010	0	2	2
2012	0	1	1
2014	0	1	1
2016	2	0	2
2017	1	0	1
2018	0	1	1
2019	1	2	3
2021	0	1	1
2022	0	2	2

Below are the most recent publications written about "CTLA-4 Antigen" by people in Profiles.

Howell AV, Gebregziabher M, Thiers BH, Graboyes EM, Paulos CM, Wrangle JM, Hunt KJ, Wallace K. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. J Geriatr Oncol. 2022 Sep; 13(7):1003-1010.

View in: PubMed
Gudi RR, Perez N, Karumuthil-Melethil S, Li G, Vasu C. Activation of T cell checkpoint pathways during ß-cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes. Immunology. 2022 07; 166(3):341-356.

View in: PubMed
Keilson JM, Knochelmann HM, Paulos CM, Kudchadkar RR, Lowe MC. The evolving landscape of immunotherapy in solid tumors. J Surg Oncol. 2021 Mar; 123(3):798-806.

View in: PubMed
Dorta-Estremera S, Hegde VL, Slay RB, Sun R, Yanamandra AV, Nicholas C, Nookala S, Sierra G, Curran MA, Sastry KJ. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. J Immunother Cancer. 2019 09 18; 7(1):252.

View in: PubMed
Gudi RR, Karumuthil-Melethil S, Perez N, Li G, Vasu C. Engineered Dendritic Cell-Directed Concurrent Activation of Multiple T cell Inhibitory Pathways Induces Robust Immune Tolerance. Sci Rep. 2019 08 19; 9(1):12065.

View in: PubMed
Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C, Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Rubinstein MP, Schuchter LM, Mitchell TC, Liu Q, Stone EL. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Ra Complexes Enhances Tumor Control. Cancer Immunol Res. 2019 08; 7(8):1371-1380.

View in: PubMed
Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018 07 11; 6(1):69.

View in: PubMed
Zhang J, Liu D, Li G, Staveley-O'Carroll KF, Graff JN, Li Z, Wu JD. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Sci Adv. 2017 May; 3(5):e1602133.

View in: PubMed
Nathanson T, Ahuja A, Rubinsteyn A, Aksoy BA, Hellmann MD, Miao D, Van Allen E, Merghoub T, Wolchok JD, Snyder A, Hammerbacher J. Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunol Res. 2017 01; 5(1):84-91.

View in: PubMed
Shields CL, Say EA, Mashayekhi A, Garg SJ, Dunn JP, Shields JA. Assessment of CTLA-4 Deficiency-Related Autoimmune Choroidopathy Response to Abatacept. JAMA Ophthalmol. 2016 07 01; 134(7):844-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals